Abstract
Edoxaban is an oral anticoagulant drug and a direct factor Xa inhibitor. However, it is still not fully understood if and how edoxaban impacts platelet function. This prospective study aimed to assess in vitro platelet function in patients with atrial fibrillation (AF) receiving edoxaban. It was a single centre study quantifying platelet aggregation in 20 patients treated with edoxaban by light transmission aggregometry. The thrombin receptor activating peptide (TRAP)-induced platelet aggregation was significantly lower 2 h after taking edoxaban compared to baseline value (44.7 ± 32.03% vs. 73.3 ± 25.55%; p < 0.0001). In addition, we did not find any significant difference in results between the patient groups.
The TRAP-induced platelet aggregation is reduced in non-valvular AF patients receiving edoxaban.
Similar content being viewed by others
References
Oung AB (2018) Edoxaban (Savaysa) for the prevention of thromboembolic events. Am Fam Physician 97:529–530
Cuker A, Husseinzadeh H (2015) Laboratory measurement of the anticoagulant activity of edoxaban: a systematic review. J Thromb Thrombolysis 39:288–294
Burnett AE, Mahan CE, Vazquez SR et al (2016) Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment. J Thromb Thrombolysis 41:206–232
Santos-Gallego CG, Badimon L, Badimón J (2014) Perspectives: direct and specific inhibition of factor Xa: an emerging therapeutic strategy for atherothrombotic disease. Eur Heart J Suppl 16:A56–A60
Plitt A, Giugliano RP (2014) Edoxaban: review of pharmacology and key phase I to III clinical trials. J Cardiovasc Pharmacol Ther 19:409–416
Mann KG, Brummel K, Butenas S (2003) What is all that thrombin for? J Thromb Haemost 1:1504–1514
Garcia-Ropero A, Santos-Gallego CG, Zafar MU, Badimon JJ (2019) Dual versus triple antithrombotic therapy: is there a role for direct oral anticoagulants in arterial thrombosis? Drugs Today (Barc) 55:197–214
Michelson AD, Ellis P, Barnard MR et al (1991) Downregulation of the platelet surface glycoprotein Ib-IX complex in whole blood stimulated by thrombin, ADP or an in vivo wound. Blood 77:770–779
Coughlin SR (2000) Thrombin signaling and protease activated receptors. Nature 407:258–264
Harrison P, Mackie I, Mumford A et al (2011) Guidelines for the laboratory investigation of heritable disorders of platelet function. Br J Haematol 155:30–44
Ivanciu L, Krishnaswamy S, Camire RM (2014) New insights into the spatiotemporal localization of prothrombinase in vivo. Blood 124:1705–1714
Ivanciu L, Stalker TJ (2015) Spatiotemporal regulation of coagulation and platelet activation during the hemostatic response in vivo. J Thromb Haemost 13:1949–1959
Rahman SM, Eichinger CD, Hlady V (2018) Effects of upstream shear forces on priming of platelets for downstream adhesion and activation. Acta Biomater 73:228–235
Davey MG, Luscher EF (1967) Actions of thrombin and other coagulant and proteolytic enzymes on blood platelets. Nature 216:857–858
Sreiff MB, Agnelli G, Connors JM et al (2016) Guidance for the treatment of deep vein thrombosis and pulmonary embolism. J Thromb Thrombolysis 41:32–67
Nehaj F, Sokol J, Ivankova J et al (2018) First Evidence: TRAP-induced platelet aggregation is reduced in patients receiving xabans. Clin Appl Thromb Hemost 24:914–919
Nehaj F, Sokol J, Mokan M et al (2018) Thrombin receptor agonist peptide-induced platelet aggregation is reduced in patients receiving dabigatran. Clin Appl Thromb Hemost 24:268–272
Eikelboom JW, Connolly SJ, Bosch J et al (2017) Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med 377:1319–1330
Santos-Gallego CG, Bayón J, Badimón JJ (2010) Thrombi of different pathologies: implications for diagnosis and treatment. Curr Treat Options Cardiovasc Med 12(3):274–291
Acknowledgements
The study was supported by Vedecká Grantová Agentúra MŠVVaŠ SR a SAV (Grant VEGA 1/0187/17) and Agentúra na Podporu Výskumu a Vývoja (Grant APVV-17-0054).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional review board and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent
Informed consent was obtained from the patient described in this report.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Nehaj, F., Sokol, J., Ivankova, J. et al. Edoxaban affects TRAP-dependent platelet aggregation. J Thromb Thrombolysis 49, 578–583 (2020). https://doi.org/10.1007/s11239-020-02093-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11239-020-02093-9